3billion Signs AI Drug Discovery Collaboration Agreement with DeepLife

“Combining genomics and AI virtual cells to improve drug development success and advance global licensing opportunities”
3billion Signs AI Drug Discovery Collaboration Agreement with DeepLife

• Co-development agreement signed at BIO-Europe 2026 to build a pipeline for future partnerships and licensing with global pharmaceutical companies
• Genomic data from more than 120,000 individuals to guide target discovery, with AI virtual cells supporting validation and the selection of promising drug candidates
• DeepLife’s AI drug discovery capabilities recognized through collaborations with international research institutions and biotechnology companies

SEOUL, South Korea, November 10, 2026 – 3billion, Inc., an AI-powered genetic diagnostics and drug discovery company, announced that it has signed a Master Co-Development Agreement with DeepLife, a French AI drug discovery company, to identify therapeutic targets using genomic data and develop novel drug candidates.

The collaboration brings 3billion’s experience analyzing genomic data from more than 120,000 individuals and its proprietary AI drug discovery technologies into a global research partnership. Through its rare disease diagnostic work, 3billion studies why people carrying the same disease-causing variant can differ in whether they develop disease and how severe their symptoms become. The company uses genetic modifiers, genes that influence these differences, to identify new therapeutic targets.

The companies aim to improve the likelihood of successful drug development by evaluating targets identified in patient genomes with AI-powered virtual cell models. Combining human genetic evidence with analysis of cellular mechanisms of action is intended to support early assessment of target validity, reduce development risk and prioritize promising drug candidates. A 2024 study published in Nature estimated that drug mechanisms supported by human genetic evidence were approximately 2.6 times as likely to progress from clinical development to approval as those without such support.

DeepLife is a French biotechnology company that developed TwinCell™, an AI virtual-cell platform. Drawing on more than 100 million single-cell omics data points and causal AI, the platform identifies key regulators of disease, analyzes cellular mechanisms of action and discovers new therapeutic targets. This year, DeepLife was selected for support through an AI innovation initiative under France 2030, France’s national investment program. The company also collaborates with international research institutions and biotechnology companies, including Centre Léon Bérard, a French cancer center, and US-based Ginkgo Bioworks.

Building on therapeutic targets identified through its analysis of genetic modifiers in patient genomes, 3billion will explore drug-binding pockets on proteins and use its proprietary AI technologies to design small-molecule drug candidates. DeepLife will apply TwinCell to analyze how these targets affect disease states and clarify their mechanisms of action at the cellular level. Together, the companies plan to establish a co-development framework spanning target discovery through drug candidate development.

The joint research will focus on discovering new targets based on genetic modifiers, analyzing and validating target mechanisms using virtual cells, and designing and optimizing small-molecule drug candidates with AI. The companies intend to develop programs across multiple therapeutic areas and generate drug discovery assets for future co-development and licensing with global pharmaceutical companies.

“Therapeutic targets supported by human genetic evidence are associated with a higher likelihood of clinical development success,” said Pavel Printsev, Chief Business Development Officer of 3billion. “By combining 3billion’s genomic analysis expertise with DeepLife’s virtual cell technology, we aim to rigorously assess the biological rationale for therapeutic targets and reduce uncertainty in early drug discovery. This will help us advance promising programs and expand opportunities for follow-on co-development and licensing with pharmaceutical companies.”

“3billion’s experience in analyzing patient genomes and its AI-driven compound design technologies provide an important foundation for discovering new therapeutic targets,” said Jonathan Baptista, Co-founder and Chief Executive Officer of DeepLife. “By combining these capabilities with DeepLife’s virtual cell technology, we aim to gain a more precise understanding of disease mechanisms, identify promising targets and open new opportunities for drug discovery.”